BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
Industry
PHARMACEUTICAL PREPARATIONS
Address
256 E. GRAND AVENUE, SUITE 104
SOUTH SAN FRANCISCO, CA 94080
Phone: 857 702 0377